EGFR ||| S:0 E:4 ||| NNP
/ ||| S:4 E:5 ||| NNP
HER2  ||| S:5 E:10 ||| NNP
inhibitors  ||| S:10 E:21 ||| VBD
effectively  ||| S:21 E:33 ||| RB
reduce  ||| S:33 E:40 ||| VB
the  ||| S:40 E:44 ||| DT
malignant  ||| S:44 E:54 ||| JJ
potential  ||| S:54 E:64 ||| NN
of  ||| S:64 E:67 ||| IN
MDR  ||| S:67 E:71 ||| NNP
breast  ||| S:71 E:78 ||| NN
cancer  ||| S:78 E:85 ||| NN
evoked  ||| S:85 E:92 ||| NN
by  ||| S:92 E:95 ||| IN
P-gp  ||| S:95 E:100 ||| JJ
substrates  ||| S:100 E:111 ||| JJ
in vitro and in vivo  ||| S:111 E:132 ||| NNP
Multidrug  ||| S:132 E:142 ||| NNP
resistance  ||| S:142 E:153 ||| NN
( ||| S:153 E:154 ||| -LRB-
MDR ||| S:154 E:157 ||| NNP
)  ||| S:157 E:159 ||| -RRB-
induced  ||| S:159 E:167 ||| VBN
by  ||| S:167 E:170 ||| IN
chemotherapy  ||| S:170 E:183 ||| NN
in  ||| S:183 E:186 ||| IN
breast  ||| S:186 E:193 ||| JJ
cancer  ||| S:193 E:200 ||| NN
frequently  ||| S:200 E:211 ||| RB
leads  ||| S:211 E:217 ||| VBZ
to  ||| S:217 E:220 ||| TO
tumor  ||| S:220 E:226 ||| NN
invasion ||| S:226 E:234 ||| NN
,  ||| S:234 E:236 ||| ,
metastasis  ||| S:236 E:247 ||| NN
and  ||| S:247 E:251 ||| CC
poor  ||| S:251 E:256 ||| JJ
clinical  ||| S:256 E:265 ||| JJ
outcome ||| S:265 E:272 ||| NN
.  ||| S:272 E:274 ||| .
We  ||| S:274 E:277 ||| PRP
preliminarily  ||| S:277 E:291 ||| VBP
found  ||| S:291 E:297 ||| VBN
that  ||| S:297 E:302 ||| IN
the  ||| S:302 E:306 ||| DT
epidermal  ||| S:306 E:316 ||| JJ
growth  ||| S:316 E:323 ||| NN
factor  ||| S:323 E:330 ||| NN
receptor  ||| S:330 E:339 ||| NN
( ||| S:339 E:340 ||| -LRB-
EGFR ||| S:340 E:344 ||| NNP
)  ||| S:344 E:346 ||| -RRB-
is  ||| S:346 E:349 ||| VBZ
involved  ||| S:349 E:358 ||| VBN
in  ||| S:358 E:361 ||| IN
enhancing  ||| S:361 E:371 ||| VBG
the  ||| S:371 E:375 ||| DT
malignant  ||| S:375 E:385 ||| JJ
potential  ||| S:385 E:395 ||| NN
of  ||| S:395 E:398 ||| IN
MDR  ||| S:398 E:402 ||| NNP
breast  ||| S:402 E:409 ||| NN
cancer  ||| S:409 E:416 ||| NN
cells ||| S:416 E:421 ||| NNS
,  ||| S:421 E:423 ||| ,
but  ||| S:423 E:427 ||| CC
the  ||| S:427 E:431 ||| DT
mechanism  ||| S:431 E:441 ||| NN
remains  ||| S:441 E:449 ||| VBZ
unclear ||| S:449 E:456 ||| JJ
.  ||| S:456 E:458 ||| .
In  ||| S:458 E:461 ||| IN
the  ||| S:461 E:465 ||| DT
present  ||| S:465 E:473 ||| JJ
study ||| S:473 E:478 ||| NN
,  ||| S:478 E:480 ||| ,
we  ||| S:480 E:483 ||| PRP
demonstrated  ||| S:483 E:496 ||| VBD
in vitro and in vivo  ||| S:496 E:517 ||| CD
that  ||| S:517 E:522 ||| IN
EGFR ||| S:522 E:526 ||| NNP
/ ||| S:526 E:527 ||| NNP
HER2  ||| S:527 E:532 ||| NNP
promote  ||| S:532 E:540 ||| VB
the  ||| S:540 E:544 ||| DT
invasive  ||| S:544 E:553 ||| NN
and  ||| S:553 E:557 ||| CC
metastatic  ||| S:557 E:568 ||| JJ
abilities  ||| S:568 E:578 ||| NNS
of  ||| S:578 E:581 ||| IN
MDR  ||| S:581 E:585 ||| NNP
breast  ||| S:585 E:592 ||| NN
cancer ||| S:592 E:598 ||| NN
.  ||| S:598 E:600 ||| .
More  ||| S:600 E:605 ||| RBR
importantly ||| S:605 E:616 ||| RB
,  ||| S:616 E:618 ||| ,
a  ||| S:618 E:620 ||| DT
new  ||| S:620 E:624 ||| JJ
function  ||| S:624 E:633 ||| NN
of  ||| S:633 E:636 ||| IN
EGFR ||| S:636 E:640 ||| NNP
/ ||| S:640 E:641 ||| NNP
HER2  ||| S:641 E:646 ||| NNP
inhibitors  ||| S:646 E:657 ||| NN
was  ||| S:657 E:661 ||| VBD
revealed  ||| S:661 E:670 ||| VBN
for  ||| S:670 E:674 ||| IN
the  ||| S:674 E:678 ||| DT
first  ||| S:678 E:684 ||| JJ
time ||| S:684 E:688 ||| NN
,  ||| S:688 E:690 ||| ,
which  ||| S:690 E:696 ||| WDT
could  ||| S:696 E:702 ||| MD
improve  ||| S:702 E:710 ||| VB
the  ||| S:710 E:714 ||| DT
treatment  ||| S:714 E:724 ||| NN
efficacy  ||| S:724 E:733 ||| NN
of  ||| S:733 E:736 ||| IN
breast  ||| S:736 E:743 ||| JJ
cancer  ||| S:743 E:750 ||| NN
by  ||| S:750 E:753 ||| IN
reversing  ||| S:753 E:763 ||| VBG
the  ||| S:763 E:767 ||| DT
MDR  ||| S:767 E:771 ||| NNP
process  ||| S:771 E:779 ||| NN
rather  ||| S:779 E:786 ||| RB
than  ||| S:786 E:791 ||| IN
by  ||| S:791 E:794 ||| IN
inhibiting  ||| S:794 E:805 ||| JJ
tumor  ||| S:805 E:811 ||| NN
growth ||| S:811 E:817 ||| NN
.  ||| S:817 E:819 ||| .
Firstly ||| S:819 E:826 ||| NNP
,  ||| S:826 E:828 ||| ,
using  ||| S:828 E:834 ||| VBG
quantitative  ||| S:834 E:847 ||| JJ
real‑time  ||| S:847 E:857 ||| NNP
PCR  ||| S:857 E:861 ||| NNP
and  ||| S:861 E:865 ||| CC
western  ||| S:865 E:873 ||| JJ
blot  ||| S:873 E:878 ||| JJ
analysis ||| S:878 E:886 ||| NN
,  ||| S:886 E:888 ||| ,
we  ||| S:888 E:891 ||| PRP
found  ||| S:891 E:897 ||| VBD
that  ||| S:897 E:902 ||| DT
overexpression  ||| S:902 E:917 ||| NN
of  ||| S:917 E:920 ||| IN
EGFR ||| S:920 E:924 ||| NNP
/ ||| S:924 E:925 ||| FW
HER2  ||| S:925 E:930 ||| FW
in  ||| S:930 E:933 ||| FW
MCF7 ||| S:933 E:937 ||| FW
/ ||| S:937 E:938 ||| FW
Adr  ||| S:938 E:942 ||| FW
cells  ||| S:942 E:948 ||| FW
upregulated  ||| S:948 E:960 ||| FW
CD147  ||| S:960 E:966 ||| FW
and  ||| S:966 E:970 ||| CC
MMP2 ||| S:970 E:974 ||| CD
/ ||| S:974 E:975 ||| CD
9  ||| S:975 E:977 ||| CD
at  ||| S:977 E:980 ||| IN
both  ||| S:980 E:985 ||| PDT
the  ||| S:985 E:989 ||| DT
transcription  ||| S:989 E:1003 ||| NN
and  ||| S:1003 E:1007 ||| CC
protein  ||| S:1007 E:1015 ||| NN
expression  ||| S:1015 E:1026 ||| NN
levels ||| S:1026 E:1032 ||| NNS
,  ||| S:1032 E:1034 ||| ,
which  ||| S:1034 E:1040 ||| WDT
promoted  ||| S:1040 E:1049 ||| VBD
tumor  ||| S:1049 E:1055 ||| JJ
cell  ||| S:1055 E:1060 ||| NN
migration ||| S:1060 E:1069 ||| NN
,  ||| S:1069 E:1071 ||| ,
as  ||| S:1071 E:1074 ||| RB
determined  ||| S:1074 E:1085 ||| VBN
using  ||| S:1085 E:1091 ||| VBG
an  ||| S:1091 E:1094 ||| DT
in vitro  ||| S:1094 E:1103 ||| JJ
invasion  ||| S:1103 E:1112 ||| NN
assay ||| S:1112 E:1117 ||| NN
.  ||| S:1117 E:1119 ||| .
Secondly ||| S:1119 E:1127 ||| RB
,  ||| S:1127 E:1129 ||| ,
the  ||| S:1129 E:1133 ||| DT
upregulated  ||| S:1133 E:1145 ||| JJ
levels  ||| S:1145 E:1152 ||| NNS
of  ||| S:1152 E:1155 ||| IN
CD147  ||| S:1155 E:1161 ||| NNP
and  ||| S:1161 E:1165 ||| CC
MMP2 ||| S:1165 E:1169 ||| CD
/ ||| S:1169 E:1170 ||| CD
9  ||| S:1170 E:1172 ||| CD
were  ||| S:1172 E:1177 ||| VBD
decreased  ||| S:1177 E:1187 ||| VBN
when  ||| S:1187 E:1192 ||| WRB
EGFR ||| S:1192 E:1196 ||| NNP
/ ||| S:1196 E:1197 ||| NNP
HER2  ||| S:1197 E:1202 ||| NNP
activity  ||| S:1202 E:1211 ||| NN
was  ||| S:1211 E:1215 ||| VBD
inhibited ||| S:1215 E:1224 ||| CD
,  ||| S:1224 E:1226 ||| ,
and  ||| S:1226 E:1230 ||| CC
therefore  ||| S:1230 E:1240 ||| RB
tumor  ||| S:1240 E:1246 ||| JJ
invasion  ||| S:1246 E:1255 ||| NN
was  ||| S:1255 E:1259 ||| VBD
also  ||| S:1259 E:1264 ||| RB
significantly  ||| S:1264 E:1278 ||| RB
inhibited ||| S:1278 E:1287 ||| VBD
.  ||| S:1287 E:1289 ||| .
These  ||| S:1289 E:1295 ||| DT
phenomena  ||| S:1295 E:1305 ||| NN
were  ||| S:1305 E:1310 ||| VBD
also  ||| S:1310 E:1315 ||| RB
demonstrated  ||| S:1315 E:1328 ||| VBN
in  ||| S:1328 E:1331 ||| IN
nude  ||| S:1331 E:1336 ||| JJ
mouse  ||| S:1336 E:1342 ||| NN
assays ||| S:1342 E:1348 ||| NN
.  ||| S:1348 E:1350 ||| .
Additionally ||| S:1350 E:1362 ||| RB
,  ||| S:1362 E:1364 ||| ,
in  ||| S:1364 E:1367 ||| IN
MDR  ||| S:1367 E:1371 ||| NNP
breast  ||| S:1371 E:1378 ||| NN
cancer  ||| S:1378 E:1385 ||| NN
patients ||| S:1385 E:1393 ||| NNS
,  ||| S:1393 E:1395 ||| ,
we  ||| S:1395 E:1398 ||| PRP
found  ||| S:1398 E:1404 ||| VBD
that  ||| S:1404 E:1409 ||| DT
overexpression  ||| S:1409 E:1424 ||| NN
of  ||| S:1424 E:1427 ||| IN
EGFR  ||| S:1427 E:1432 ||| NNP
and  ||| S:1432 E:1436 ||| CC
P‑gp  ||| S:1436 E:1441 ||| CD
levels  ||| S:1441 E:1448 ||| NNS
led  ||| S:1448 E:1452 ||| VBN
to  ||| S:1452 E:1455 ||| TO
shorter  ||| S:1455 E:1463 ||| VB
overall  ||| S:1463 E:1471 ||| JJ
survival  ||| S:1471 E:1480 ||| NN
( ||| S:1480 E:1481 ||| -LRB-
OS ||| S:1481 E:1483 ||| NNP
)  ||| S:1483 E:1485 ||| -RRB-
and  ||| S:1485 E:1489 ||| CC
disease‑free  ||| S:1489 E:1502 ||| CD
survival  ||| S:1502 E:1511 ||| NN
( ||| S:1511 E:1512 ||| -LRB-
DFS ||| S:1512 E:1515 ||| NNP
)  ||| S:1515 E:1517 ||| -RRB-
by  ||| S:1517 E:1520 ||| IN
IHC  ||| S:1520 E:1524 ||| NNP
assays  ||| S:1524 E:1531 ||| NN
and  ||| S:1531 E:1535 ||| CC
Kaplan‑Meier  ||| S:1535 E:1548 ||| CD
survival  ||| S:1548 E:1557 ||| NN
analysis ||| S:1557 E:1565 ||| NN
.  ||| S:1565 E:1567 ||| .
In  ||| S:1567 E:1570 ||| IN
conclusion ||| S:1570 E:1580 ||| NN
,  ||| S:1580 E:1582 ||| ,
EGFR ||| S:1582 E:1586 ||| NNP
/ ||| S:1586 E:1587 ||| NNP
HER2  ||| S:1587 E:1592 ||| NNP
play  ||| S:1592 E:1597 ||| VB
a  ||| S:1597 E:1599 ||| DT
crucial  ||| S:1599 E:1607 ||| JJ
role  ||| S:1607 E:1612 ||| NN
in  ||| S:1612 E:1615 ||| IN
enhancing  ||| S:1615 E:1625 ||| VBG
CD147  ||| S:1625 E:1631 ||| NNP
and  ||| S:1631 E:1635 ||| CC
MMP  ||| S:1635 E:1639 ||| NNP
expression  ||| S:1639 E:1650 ||| NN
to  ||| S:1650 E:1653 ||| TO
establish  ||| S:1653 E:1663 ||| VB
favorable  ||| S:1663 E:1673 ||| JJ
conditions  ||| S:1673 E:1684 ||| NNS
for  ||| S:1684 E:1688 ||| IN
invasion ||| S:1688 E:1696 ||| CD
/ ||| S:1696 E:1697 ||| CD
metastasis  ||| S:1697 E:1708 ||| NN
in  ||| S:1708 E:1711 ||| IN
MDR  ||| S:1711 E:1715 ||| NNP
breast  ||| S:1715 E:1722 ||| NN
cancer ||| S:1722 E:1728 ||| NN
.  ||| S:1728 E:1730 ||| .
The  ||| S:1730 E:1734 ||| DT
scope  ||| S:1734 E:1740 ||| NN
of  ||| S:1740 E:1743 ||| IN
application  ||| S:1743 E:1755 ||| NN
of  ||| S:1755 E:1758 ||| IN
EGFR ||| S:1758 E:1762 ||| NNP
/ ||| S:1762 E:1763 ||| NNP
HER2  ||| S:1763 E:1768 ||| NNP
inhibitors  ||| S:1768 E:1779 ||| NN
may  ||| S:1779 E:1783 ||| MD
be  ||| S:1783 E:1786 ||| VB
expanded  ||| S:1786 E:1795 ||| VBN
in  ||| S:1795 E:1798 ||| IN
EGFR ||| S:1798 E:1802 ||| NNP
/ ||| S:1802 E:1803 ||| CD
HER2‑positive  ||| S:1803 E:1817 ||| CD
patients ||| S:1817 E:1825 ||| NNS
.  ||| S:1825 E:1827 ||| .
We  ||| S:1827 E:1830 ||| PRP
suggest  ||| S:1830 E:1838 ||| VBP
that  ||| S:1838 E:1843 ||| IN
MDR  ||| S:1843 E:1847 ||| NNP
breast  ||| S:1847 E:1854 ||| NN
cancer  ||| S:1854 E:1861 ||| NN
patients  ||| S:1861 E:1870 ||| NNS
may  ||| S:1870 E:1874 ||| MD
benefit  ||| S:1874 E:1882 ||| VB
from  ||| S:1882 E:1887 ||| IN
novel  ||| S:1887 E:1893 ||| NN
therapies  ||| S:1893 E:1903 ||| NNS
targeting  ||| S:1903 E:1913 ||| VBG
EGFR ||| S:1913 E:1917 ||| NNP
/ ||| S:1917 E:1918 ||| NNP
HER2 ||| S:1918 E:1922 ||| NNP
.  ||| S:1922 E:1924 ||| .
